Description
Novartis: Spinning Off Sandoz—Will a Focused Strategy Pay Off?
Novartis reported strong financial results for both the fourth quarter and full year of 2024, marking one of the most robust performances in its history. The company recorded a 16% increase in sales in the fourth quarter and a 29% rise in core operating income, both in constant currency. For the full year, sales grew 12%, while core operating income expanded by 22%, with an operating margin reaching 38.7%. Free cash flow also rose 24% to a record high of EUR 16.3 billion.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures
Want unlimited access to our reports? Purchase our $99 annual subscription!
